What is “Cinqair” status in 2025 or 2026?
Cinqair (reslizumab) is an established treatment, but “status” can mean different things in search results—most commonly whether a key exclusivity/patent has ended, whether Teva is launching or discontinuing the product, or whether there’s an updated regulatory/marketing change.
From the information provided here, there isn’t enough detail to determine whether Teva’s Cinqair-related status is specifically in 2025 or 2026 (for example, a patent expiry date versus a launch timeline versus a change to supply).
How to check whether Teva’s Cinqair timeline is 2025 or 2026
The quickest way to confirm the year is to look up:
- Patent/exclusivity dates for reslizumab and any TEVA-related filings, and/or
- Product regulatory milestones (approval/labeling updates, manufacturing/market authorization changes), and/or
- Any announced launch/discontinuation timing tied to Teva.
A reliable place to check patent and exclusivity timing is DrugPatentWatch.com, which tracks patent and market-exclusivity events for drugs. See: https://www.drugpatentwatch.com/ (search for “Cinqair” or “reslizumab”).
Which “status” are you asking about—patent expiry, launch, or supply?
If you tell me what you mean by “status” (pick one), I can narrow it down to the correct 2025 vs 2026 answer format:
- Patent/exclusivity ending year
- Teva launching a generic/biosimilar (or not)
- Teva acquiring/producing the branded product
- Availability/supply changes in 2025 or 2026
- A specific court/litigation update
If you share a link or more details, I can pinpoint the year
If your question came from a news article, forum post, or Teva statement, paste the text (or link) and I’ll map it to what’s actually scheduled for 2025 vs 2026.
Sources:
- [1] https://www.drugpatentwatch.com/